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Background: In a recent study conducted in a family medicine setting, the medication acamprosate was
found not to be efficacious in the treatment of alcohol dependence, but a drinking goal of abstinence
was found to have positive effects on alcohol use outcomes. The purpose of this secondary analysis was
to further understand which patients with an alcohol use disorder may be most successfully treated in a
primary care setting.
Methods: The study was exploratory and used a trajectory-based approach based on data from the
acamprosate treatment trial of 100 participants (recruited mostly by advertisement) who were randomly
assigned to receive either acamprosate or a matching placebo. Post hoc trajectories of alcohol use be-
fore treatment were identified to examine whether trajectory classes and their interactions with treat-
ment arm (acamprosate or placebo), pretreatment drinking goal (abstinence or a reduction), and time
predicted alcohol use outcomes.
Results: Three distinct trajectory classes were identified: frequent drinkers, nearly daily drinkers,
and consistent daily drinkers. Consistent daily drinkers with a goal of abstinence significantly improved
over time on the primary outcome measure of percent days abstinent when compared with frequent and
nearly daily drinkers. In addition, all participants with a goal of abstinence, regardless of trajectory
class, significantly reduced their percentage of heavy drinking days over time.
Conclusions: Patients with an alcohol use disorder who have a drinking goal of abstinence, in partic-
ular consistent daily drinkers, may maximally benefit from alcohol use disorder treatment, including
the use of medication, in a primary care setting. (J Am Board Fam Med 2016;29:37–49.)
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For the past 30 years and more, alcohol interven-
tion clinicians and researchers have viewed the pri-
mary care setting as a logical place in which to
intervene with individuals who misuse alcohol.1–3
In particular, primary care and other community
settings have been identified as locations in which
to address nondependent or nondisordered alcohol
use as part of primary and secondary prevention
efforts.1,2 At present there exists a substantial body
of evidence on the effectiveness of alcohol screen-
ing and brief interventions among primary care
patients with nondependent but excessive alcohol
use.4 Yet, in terms of disordered alcohol use, phy-
sicians have long recognized the difficulty of treat-
ing alcohol-related medical conditions if an alcohol
use disorder is not treated alongside such medical
ailments.5 Some recent national efforts have called
for primary care clinicians to treat alcohol-depen-
dent patients with pharmacotherapy, brief behav-
ioral counseling, and alcoholism disease manage-
ment.6
Few studies to date, however, have focused on
the treatment of alcohol-dependent patients (per
the Diagnostic and Statistical Manual of Mental Dis-
eases, 4th Edition [DSM-IV])7 or, now, patients with
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an alcohol use disorder per the Diagnostic and Sta-
tistical Manual of Mental Diseases, 5th Edition)8 in
primary care settings. In a recent review, Saitz9
found no evidence of the efficacy of opportunistic
alcohol screening and brief intervention for alco-
hol-dependent patients in primary care. Yet inves-
tigators of other primary care studies, in which
alcohol-dependent patients were not necessarily
identified by alcohol screening, found behavioral
counseling and behavioral counseling with medica-
tion (acamprosate or naltrexone) to be efficacious/
effective.10–12 For example, in a pragmatic study in
which French generalist practitioners offered rou-
tine care to alcohol-dependent patients, Malet and
colleagues10 found that visit frequency and visits in
which alcohol use was addressed were both signif-
icantly associated with patient detoxification in
which patients stopped drinking for a period of
time. In other studies of alcohol-dependent or al-
cohol-abusing individuals, mostly in alcohol treat-
ment settings but also in primary care–only set-
tings, investigators found associations between a
drinking goal of abstinence and improved alcohol
use outcomes.13–17 Finally, although not in a purely
primary care setting, a trajectory-based investiga-
tion of alcohol use before treatment assignment
among alcohol-dependent individuals revealed that
very frequent drinkers, defined as a 75% probabil-
ity of any alcohol use on a given day, benefited from
acamprosate in that they were more likely to ab-
stain from heavy drinking during the past 2 months
of treatment.18 In that same investigation, very fre-
quent drinkers also benefited from the medication
naltrexone in that they were more likely to be
continuously abstinent.18 An advantage of a trajec-
tory-based approach is that it may identify a
group(s) of individuals for whom alcohol treat-
ments, including medications, could be effective.18
This study is a secondary analysis of a placebo-
controlled trial of acamprosate treatment in a fam-
ily medicine setting in which no significant effect of
acamprosate was found, but a drinking goal of ab-
stinence was found to have robust, positive effects
on drinking outcomes.14 The purpose of the cur-
rent study was to use a trajectory approach to un-
derstand further which patients with an alcohol use
disorder may be most successfully treated in a pri-
mary care setting. The study aims were to identify
trajectories of pretreatment alcohol use, describe
participants in these trajectories, and examine
whether the trajectories predict alcohol use out-
comes and/or moderate treatment response to
acamprosate. Drinking goal was also examined as
an empirically supported predictor of drinking out-
comes. This is, to our knowledge, the first study to
apply a trajectory-based approach to clinical trial
data collected in a primary care setting regarding
the treatment of alcohol use disorder.
Methods
Study Design
The study was exploratory and involved a second-
ary analysis of data collected between July 2006 and
April 2008 as part of a randomized, double-blind,
placebo-controlled study of acamprosate in the
treatment of alcohol-dependent individuals re-
cruited from 2 family medicine sites: the Family
Practice Center, University of North Carolina at
Chapel Hill, and the Aurora Health Care Center,
Mayfair Family Practice and Primary Care Clinics,
Milwaukee, Wisconsin. The medication acampro-
sate (Campral; Forest Laboratories, New York,
NY) was approved in 2004 by the US Food and
Drug Administration for the maintenance of absti-
nence in alcohol-dependent individuals who, at the
time of medication initiation, also are receiving
psychosocial support.19 As a result, participants in
the acamprosate treatment trial (hereafter referred
to as “the parent study”) had to have at least 3 days
of abstinence before treatment randomization, and,
in addition to either receiving acamprosate or pla-
cebo, participants also received 5-, 20-, or 30-min-
ute sessions of brief behavioral counseling from a
family practice or primary care physician. These
sessions were held at each of the 5 study visits:
screening, randomization/baseline (week 0, which
occurred once a participant had at least 3 days of
abstinence), and weeks 2, 6, and 12.
The brief behavioral counseling intervention
was based on the one developed and implemented
in community-based primary care clinics by Flem-
ing and colleagues.20 Because participants in the
parent study were alcohol dependent, the interven-
tion implemented by Fleming et al was expanded
from 2 to 5 sessions, and the session time increased
from 15 to 20 minutes, with the exception of the
first session, which was 30 minutes in duration. An
intervention workbook guided session discussions
between study physicians and participants and in-
cluded both motivational and cognitive-behavioral
intervention components.21 Alcoholics Anonymous
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attendance also was encouraged but not required.
Specifically, the brief behavioral counseling inter-
vention focused on alcohol use patterns and nega-
tive consequences, personalized feedback on alco-
hol use, reasons for and against change in one’s
alcohol use, drinking goal (abstinence or a self-
defined reduction in alcohol use), and strategies for
coping with alcohol cravings and risky alcohol use
situations. Study physicians encouraged partici-
pants to read and complete workbook sections be-
tween sessions. In addition to discussions of medi-
cation adherence and side effects, participants’
drinking goals were monitored and risky alcohol
use situations reviewed at each session. Finally,
standardized training was provided to study physi-
cians at the beginning of the study, and fidelity to
the brief behavioral counseling intervention was
monitored and maintained by regularly scheduled
conference calls between the 2 study sites.
Sample
Participants in the parent study included 100 male
and female outpatients between the ages of 21 to 65
years who had a current DSM-IV diagnosis of al-
cohol dependence.7,22 Individuals with a history of
alcohol withdrawal seizure or delirium tremens
were excluded from participation because of the
potential need for more intensive care. Individuals
who recently completed medical detoxification,
however, were considered for study enrollment.
Participants were recruited via provider referral
(10%), but mostly through newspaper and radio
advertising (90%). Study participants were mostly
male (62%), non-Hispanic white (91.9%), married
(63%), and were, on average, 47 years of age (mean,
47.2 years; standard deviation [SD], 8.06 years).
Less than half (47%) had a college education, and
slightly more than half (60%) were enrolled at the
University of North Carolina at Chapel Hill; 40%
were enrolled at the Milwaukee, Wisconsin, site.
The parent study was approved by the institutional
review boards at the 2 study sites, and methods of
the parent study are described in greater detail
elsewhere.14
Measures/Variables
In this study the primary and secondary alcohol use
outcome variables, respectively, were percentage of
days abstinent (PDA) and percent heavy drinking
days (%HDD) as derived from the interviewer-
administered Timeline Followback (TLFB) mea-
sure.23,24 The TLFB is a retrospective, calendar-
based instrument used to record daily alcohol
consumption in US standard drink units (1 stan-
dard drink  14 g ethanol)25 and was adminis-
tered at screening, randomization/baseline (week
0), and study weeks 2, 6, and 12. Several TLFB
administration techniques were used to enhance
the accuracy of participant self-report, such as the
use of recall aids (eg, local events typed into the
calendar to help with recall).26 Heavy drinking days
were defined as 4 US standard drinks per drink-
ing day for women, and 5 US standard drinks per
drinking day for men.25 The screening TLFB data
also were used to identify trajectories of alcohol use
before treatment.
Drinking goal was assessed at the screening visit
as part of interviewer-administered enrollment forms.
Participants considered and selected a drinking goal
of either abstinence (37%) or a self-defined reduc-
tion in alcohol use (63%) before meeting with a
study physician. There was no significant differ-
ence between study site and participant selection of
a drinking goal.
Finally, we also used several clinical characteris-
tic and sociodemographic variables as assessed/re-
corded at the screening visit. The clinical charac-
teristic variables included 2 alcohol dependence
severity variables as assessed by the interviewer-
administered Structured Clinical Interview for
DSM-IV.22 The first variable was the severity of
participant alcohol dependence for the worst week
in the past month. Study-trained interviewers cat-
egorized severity as mild, moderate, or severe based
on impairment in the participants’ occupational
functioning, social activities, or relationships. The
second severity variable as assessed by the Struc-
tured Clinical Interview for DSM-IV was whether
there was current evidence of physiologic depen-
dence, based on participant experience of tolerance
and/or withdrawal symptoms in the past 3 months.
Another clinical characteristic variable was -glu-
tamyl transferase, a relatively specific biomarker of
continuous heavy alcohol use27; based on concen-
tration, participants were categorized as either hav-
ing normal or high (78 units/L) -glutamyl trans-
ferase. Additional clinical characteristic variables
included total score on 2 commonly used self-re-
port alcohol screening measures in primary care
settings: the 10-item Alcohol Use Disorders Identifi-
cation Test (scoring range, 0–40),28 and the 4-item
CAGE questionnaire (scoring range, 0–4).29 Finally,
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the Clinical Global Impression Scale (scoring range,
1–7)30 was also used by study physicians to globally
assess the severity of participants’ alcohol depen-
dence.
Sociodemographics, which were collected as
part of the interviewer-administered enrollment
forms, included the dichotomous variables of sex,
racial/ethnic minority status, college education,
married, current tobacco use, family history of al-
coholism, previous alcohol treatment (defined as
mutual-support help, outpatient counseling, and/or
inpatient detoxification), and the continuous vari-
ables of age and years of alcohol use. The family
history of alcoholism variable was based on a mod-
ified version of the Family Tree Questionnaire for
Assessing Family History of Alcohol Problems,31 in
which a participant was considered to have a family
history if any first- or second-degree relatives had
or have a drinking problem.
Data Analysis
Latent class growth modeling,32 which assumed
fixed polynomial trends over time, was used to
identify distinct trajectory classes based on the
probability of any pretreatment alcohol use on a
given day. Screening data from the TLFB, which
included 87 of the 90 days before the random-
ization/baseline visit (week 0), were used to iden-
tify trajectory classes. Because acamprosate is ap-
proved by the US Food and Drug Administration
for the maintenance of abstinence, participants in
the parent study were required to have at least 3
days of abstinence before the randomization/
baseline visit. These 3 days of abstinence for each
participant were removed to reflect a more nat-
ural course of participant alcohol use. Thus, us-
ing the 87 days of the TLFB data, a daily dichot-
omous variable of any alcohol use was created
for each participant for the trajectory analysis.
Final trajectory classes were chosen based on fit
to the data as assessed by the Schwartz Bayesian
criterion and having at least 5% of participants in
each trajectory class. A categorical variable of
trajectory classes was created to compare so-
ciodemographic and clinical characteristics of
participants in each class using the 2 test (or the
Fisher’s exact test if the expected count[s] were
	5), and analysis of variance with Tukey hon-
estly significant difference post hoc tests
(Welch’s analysis of variance was used if vari-
ances were unequal). Based on the work of
Nagin,33 PROC TRAJ, which was developed by
Jones and colleagues,34 was used to identify tra-
jectory classes.
In addition, growth curve models were run
whereby identified trajectory classes, treatment arm
(acamprosate or placebo), and time (screening/
baseline, weeks 2, 6, and 12) were entered as fixed
effects and their interactions examined. The longi-
tudinal covariance matrices were specified as un-
structured, and time was not specified as random
slopes because of the small sample size. Likewise,
other variables were unable to be entered as fixed
effects because of the small sample size. The PDA
and %HDD outcome variables were arcsine trans-
formed before analysis because of positive skew,
and all available TLFB data were used, including
up until the point of drop out if participants did not
complete the parent study (19% attrition). Because
the treatment arm variable (acamprosate or pla-
cebo) was not statistically significant in either alco-
hol use outcome analysis, the variable was removed
from the models and the drinking goal added. For
all statistically significant growth curve model re-
sults, Cohen’s f2 was used to calculate effect sizes
(0.02 was considered a small effect, 0.15 a medium
effect, and 0.35 a large effect35). SAS Mixed Pro-
cedure 9.4 (SAS Inc., Cary, NC) was used to run
the growth curve models.36,37
Results
Three distinct trajectory classes of pretreatment
alcohol use were identified: frequent drinkers, rep-
resenting 21% of participants, had a 52% average
probability of any alcohol use on a given day (linear
trend over time); nearly daily drinkers, represent-
ing 28.5% of participants, had a 78% average prob-
ability of any drinking on a given day (cubic trend
over time); and consistent daily drinkers, represent-
ing 50.5% of participants, had a 97% average prob-
ability of any alcohol use on a given day (cubic
trend over time) (entropy was 0.9638; Figure 1).
Both nearly daily and consistent daily drinkers no-
tably reduced their alcohol use before the required
3 days of abstinence before the randomization/
baseline visit, whereas the drinking pattern of fre-
quent drinkers remained relatively unchanged be-
fore randomization.
To describe participants in these trajectories,
Table 1 presents the sociodemographic and clin-
ical characteristics, including screening PDA and
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%HDD, of participants in each of the 3 trajectory
classes. Frequent (81%) and consistent daily drink-
ers (62.8%) were more likely to be male than fe-
male when compared with nearly daily drinkers
(46.4%), and consistent daily drinkers (58.8%)
were more likely to have a college education than
both frequent (28.6%) and nearly daily drinkers
(39.3%). Frequent drinkers (61.9%) also were less
likely to be physiologically dependent on alcohol in
comparison with both nearly daily (83.3%) and
consistent daily drinkers (89.6%). Consistent daily
drinkers (23.5%) were less likely to select a drink-
ing goal of abstinence versus a reduction in alcohol
use in comparison to both frequent (50%) and
nearly daily drinkers (53.6%). Furthermore, fre-
quent drinkers (mean, 42.7 years; SD, 7.3 years)
were statistically younger, on average, than consis-
tent daily drinkers (mean, 48.6 years; SD, 8.0
years), and all 3 trajectory classes were statistically
different from one another on both screening
PDA—a mean (SD) 51.0 (8.9), 26.4 (7.4), and 6.4
(3.0) for frequent, nearly daily, and consistent
daily drinkers, respectively—and %HDD, with
42.1 (10.5), 60.0 (16.2), and 80.0 (23.3) for fre-
quent, nearly daily, and consistent daily drinkers,
respectively.
Table 2 presents the results of the growth curve
models of trajectory class, drinking goal, and time
for PDA and %HDD. There was a significant
3-way interaction of trajectory class, drinking goal,
and time (F(2,284)  7.54; f2  0.05; 95% confi-
dence interval [CI], 0.03–0.33) for PDA (Figure 2A
and B). Participants within each trajectory class
with a drinking goal of abstinence relative to a
reduction in alcohol use had higher average PDA
over time. Interaction contrasts, however, revealed
no significant difference between frequent and
nearly daily drinkers across the 2 levels of drinking
goal over time (based on both linear and quadratic
trends), but consistent daily drinkers were signifi-
cantly different from frequent and nearly daily
drinkers (these 2 classes averaged) (F(1,277) 
20.59, P 	 .001 for linear trend; F(1,268)  10.37,
P 	 .01 for quadratic trend). That is, consistent
daily drinkers with a goal of abstinence experienced
a significant, positive change on PDA over time
(mean PDA, 5.0 [SD, 1.1] at screening/baseline to
80.1 [31.3] at week 12) when compared with their
Figure 1. Probability of any alcohol use over time before screening by trajectory class (n 100). Group
percentages are 21% for frequent drinkers (yellow), 28.5% for nearly daily drinkers (orange), and 50.5% for
consistent daily drinkers (red). The lines and markers represent the observed probability of any alcohol use
among participants within each trajectory class on each day during the screening period. Dotted lines represent
the predicted probability of any alcohol use among participants within each trajectory class on a given day during
the screening period.
Group Percentages are:    Frequent Drinkers = 21%;    Nearly Daily Drinkers = 28.5%; and 
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Table 1. Sociodemographic and Clinical Characteristics of the Three Trajectory Classes at Screening (n 100)
Frequent Drinkers
(n  21)
Nearly Daily Drinkers
(n  28)
Consistent Daily Drinkers
(n  51)
Sex*
Male 81.0 46.4 62.8
Female 19.0 53.6 37.2
Race/ethnicity†
Nonminority 85.7 96.3 92.2
Minority 14.3 3.7 7.8
College education*
Yes 28.6 39.3 58.8
No 71.4 60.7 41.2
Married
Yes 61.9 57.1 66.7
No 38.1 42.9 33.3
Current tobacco use
Yes 57.1 53.6 33.3
No 42.9 46.4 66.7
Family history of alcoholism†
Yes 90.0 92.6 96.0
No 10.0 7.4 4.0
Previous alcohol treatment
Yes 60.0 60.0 37.5
No 40.0 40.0 62.5
Severity of alcohol dependence†
Mild 5.0 11.1 8.5
Moderate 95.0 70.4 68.1
Severe 0.0 18.5 23.4
Physiological dependence*†
Yes 61.9 83.3 89.6
No 38.1 16.7 10.4
GGT level
High 23.8 33.3 40.0
Normal 76.2 66.7 60.0
Drinking goal*
Abstinence 50.0 53.6 23.5
Reduction in use 50.0 46.4 76.5
Condition
Acamprosate 47.6 53.6 51.0
Placebo 52.4 46.4 49.0
Age (years)* 42.7 (7.3) 47.8 (7.7) 48.6 (8.0)
Duration of alcohol use (years) 24.4 (8.5) 26.6 (8.1) 26.5 (10.4)
AUDIT total score 23.0 (5.6) 24.0 (5.9) 22.4 (5.2)
CAGE total score 2.7 (1.0) 3.0 (0.8) 2.6 (0.7)
CGI score 2.8 (1.5) 3.7 (1.5) 3.5 (1.8)
Percent days abstinent‡ 51.0 (8.9) 26.4 (7.4) 6.4 (3.0)
Percent heavy drinking days‡ 42.1 (10.5) 60.0 (16.2) 80.0 (23.3)
Data are either a percentage or mean (standard deviation). All sociodemographic and clinical characteristic variables had7% missing
data with the exception of previous treatment, which had 28% missing data.
*P 	 .05.
†Fisher exact test.
‡P 	 .001.
AUDIT, Alcohol Use Disorders Identification Test; CGI, Clinical Global Impression Scale.
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counterparts with a goal of reduction in alcohol use
(mean PDA, 6.9 [SD, 3.2] at screening/baseline to
26.1 [30.3] at week 12) as compared with the com-
bination of both frequent and nearly daily drinkers
(mean PDA, 39.2 [SD, 16.8] at screening/baseline
to 79.1 [23.9] at week 12 for frequent and nearly
daily drinkers with a goal of abstinence, and 34.1
[12.0] at screening/baseline to 63.8 [31.0] at week
12 for frequent and nearly daily drinkers with a goal
of alcohol use reduction). Participants in all 3 tra-
jectory classes, regardless of drinking goal, also
increased the most on PDA between baseline and
study week 2.
There was a significant 2-way interaction of tra-
jectory class and time (F(2,284)  3.23; f2  0.02;
95% CI, 0.00–0.19) for %HDD (Figure 3). Fre-
quent and nearly daily drinkers, relative to consis-
tent daily drinkers, achieved approximately the
same levels of average improvement in reducing
%HDD over time, and interaction contrasts re-
vealed this difference to be significant (F(1,276) 
6.01, P 	 .05 for linear trend; F(1,268)  16.63,
P 	 .001 for quadratic trend). That is, consistent
daily drinkers had higher average %HDD over
time (mean [SD] of 80.0% [23.3%] at screening/
baseline to 32.4% [35.0%] at week 12) when com-
pared with the combination of both frequent and
nearly daily drinkers (52.4 [16.6%] at screening/
baseline to 13.4% [20.8%] at week 12). In addition,
participants in all 3 trajectory classes decreased the
most on %HDD between baseline and study week
2. There was also a significant 2-way interaction of
drinking goal and time (F(1,284)  6.63; f2  0.04;
95% CI, 0.03–0.21) for %HDD (Figure 4). Partic-
ipants with a drinking goal of abstinence relative to
a reduction in alcohol use had lower average
%HDD over time (66.0% [23.4%] at screening/
baseline to 11.3% [22.0%] at week 12 for partici-
pants with a goal of abstinence, and 67.2% [25.2%]
at screening/baseline to 31.0% [33.0%] at week 12
for participants with a goal of alcohol use reduc-
tion); interaction contrasts revealed this difference
to be significant (F(1,278)  10.52, P 	 .01 for
linear trend; F(1,268)  15.47, P 	 .001 for qua-
dratic trend). Participants, regardless of drinking
goal, also decreased the most on %HDD between
baseline and study week 2.
Discussion
The results of this secondary analysis reveal that
both trajectories of alcohol use and endorsed drink-
ing goal before treatment affect alcohol use out-
comes for patients with an alcohol use disorder
when treated with brief behavioral counseling in
the context of a clinical trial in a primary care
setting. The 3 identified trajectory classes of pre-
treatment alcohol use in this study behaved simi-
larly to 3 of 5 trajectory classes identified in previ-
ous work by Gueorguieva and colleagues18 and thus
were titled the same: frequent drinkers, nearly daily
drinkers, and consistent daily drinkers. Most nota-
bly, consistent daily drinkers who endorsed a goal
of abstinence had about a two-thirds gain in PDA
over time versus their counterparts who wanted to
reduce their alcohol use. A drinking goal of absti-
nence for individuals who are consuming alcohol
on a consistent daily basis may have the ability to
modify PDA in a positive direction. Although con-
sistent daily drinkers had significantly higher
%HDD than frequent and nearly daily drinkers
over time, participants, including consistent daily
Table 2. Growth Curve Models of Trajectory Class, Drinking Goal, and Time on Percent Days Abstinent and
Percent Heavy Drinking Days (n 100)
Variables
PDA %HDD
Num df Den df F P Num df Den df F P
Trajectory class 2 216 9.75 	.001 2 216 6.76 	.01
Drinking goal 1 216 5.56 	.05 1 216 0.26 .61
Time 1 284 89.5 	.001 1 284 128.5 	.001
Trajectory class 
 drinking goal 2 216 0.02 .98 2 216 0.08 .92
Trajectory class 
 time 2 284 4.15 	.05 2 284 3.23 	.05
Drinking goal 
 time 1 284 11.67 	.01 1 284 6.63 	.05
Trajectory class 
 drinking goal 
 time 2 284 7.54 	.01 2 284 2.14 .12
%HDD, percent heavy drinking days; PDA, percent days abstinent; Num df, numerator degrees of freedom; Den df, denominator
degrees of freedom.
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drinkers, who endorsed a goal of abstinence versus
a reduction in alcohol use had about one-third
the %HDD over time. A drinking goal of absti-
nence seems to be associated with reductions in
%HDD—a positive outcome beyond gains in PDA
only such that those participants with a goal of
abstinence had, on average, slightly10% HDD at
week 12 (compared with an average of 66% HDD
at screening/baseline). Finally, the trajectory classes
did not interact with acamprosate on either PDA or
%HDD, and because of the small sample size,
we—unlike Gueorguieva and colleagues18—were
unable to consider the outcome measure of absti-
nence from heavy drinking during the past 2
months of treatment. That is, Gueorguieva and
colleagues18 found that frequent drinkers who re-
ceived acamprosate were more likely to abstain
from heavy drinking during this time period.
Figure 2. Pretreatment goals of reduction in alcohol use (n  62) (A) and abstinence (n  37) (B) by
trajectory classes over time on percent days abstinent (untransformed). Error bars represent the standard
deviation.
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Practical Implications
Based on our results, there may be value to assess-
ing drinking trajectories among patients in a pri-
mary care setting who need treatment for an alco-
hol use disorder. Assessing such trajectories may
potentially be accomplished through the adminis-
tration of alcohol use frequency measures, though
no formal instrument to do this has yet been de-
veloped. Positive changes in drinking behavior of-
ten occur before the start of treatment, and captur-
ing such pretreatment change via trajectories may
allow for a fuller picture of the change process.39
Furthermore, drinking goal before treatment,
which was assessed in the parent study via simple
verbal inquiry, also seems to be clinically meaning-
ful. That is, patients with a goal of abstinence may
be more responsive to alcohol use disorder treat-
ment in a primary care setting,14 which seems to be
the case in alcohol treatment settings as well.13,15–17
It should also be noted that pretreatment alcohol
use seems to be associated with pretreatment drink-
ing goal. Both frequent and nearly daily drinkers
versus consistent daily drinkers were more likely to
select a goal of abstinence; yet, based on our growth
curve models, consistent daily drinkers with a goal
of abstinence made significantly notable gains in
PDA, which may be a counterintuitive finding
given the frequency of drinking among participants
in this trajectory class. Specifically, consistent daily
drinkers with a goal of abstinence had an average of
5% of days abstinent at screening/baseline, which
was similar to the average of 7% of days abstinent
at screening/baseline for consistent daily drinkers
with a goal of reduction in alcohol use. At the end
of treatment (week 12), however, consistent daily
drinkers with a goal of abstinence had an average of
80% of days abstinent when compared with an
average of 26% of days abstinent for consistent
daily drinkers with a goal of reduction in alcohol
use. Furthermore, although consistent daily drink-
ers and the combination of both frequent and
nearly daily drinkers with a goal of abstinence, who
had an average of 39% of days abstinent at screen-
ing/baseline, ended treatment (week 12) with es-
sentially the same outcome—80% PDA for consis-
tent daily drinkers and 79% PDA for the
combination of frequent and nearly daily drink-
ers—consistent daily drinkers with a goal of absti-
nence made greater strides in achieving PDA from
screening/baseline. Finally, our results reveal that
most patient change on both PDA and %HDD
occurred within the first 2 weeks of treatment and
was more or less maintained until study end,
thereby suggesting that positive change may be
able to happen in a short period of time in a pri-
mary care setting. The longer-term maintenance of
Figure 3. Pretreatment trajectory classes over time on percent heavy drinking days (untransformed; n 100).
Error bars represent the standard deviation.
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such change in a primary care setting, however, is
unknown.
Treatment of Alcohol Use Disorder by Primary Care
Physicians
Given the interest in primary care settings as loca-
tions in which to address alcohol misuse, and the
recent interest in integrated care for individuals
with co-occurring substance use, mental health
conditions, and medical conditions,40,41 primary
care physicians will likely become more involved in
the treatment of individuals with an alcohol use
disorder, assuming such patients are not too ill.
The results of this secondary analysis draw atten-
tion to the role of drinking goal in a primary care
setting. Specifically, a goal of abstinence may be an
important moderator for a good outcome in a pri-
mary care setting. It will be important to under-
stand through future research how patients arrive
at such a goal, and equally important to understand
how primary care physicians can facilitate patients
toward such a goal. Unlike trajectories of pretreat-
ment alcohol use, treatment interventions may al-
low a physician to address and negotiate a drinking
goal with patients.42–46 But, will a negotiated goal
of abstinence have the same positive outcome as a
“natural” goal of abstinence, as seen in these find-
ings? Potential interventions to help patients move
toward a goal of abstinence include motivational
interviewing,42 the sobriety sampling procedure43
of the community reinforcement approach,44 and
practitioner acceptance of a moderation goal,45
which, when accepted, may lead to an abstinence
goal, as detailed in behavioral self-control train-
ing.45,46 Although to date there is no evidence of
the efficacy of brief intervention for patients with
alcohol dependence or very heavy drinking in pri-
mary care as identified by screening,9 certain as-
pects that may make opportunistic brief interven-
tion successful for individuals without an alcohol
use disorder in primary care may also be relevant
for the management of primary care patients with
an alcohol use disorder. In particular, one impor-
tant aspect may be the existence of an established
patient–physician relationship (in which rapport
and trust exist47) in which to implement effective
alcohol use disorder treatment.
An important component of this study is that
participants took pills throughout the parent study,
and because of how acamprosate is administered,
this consisted of taking 2 pills 3 times a day. This
represents an intervention regardless of pharmacol-
ogy, and in fact, no effect of acamprosate was
found. In an intriguing analysis of the effect of
Figure 4. Pretreatment goal of abstinence versus a reduction in alcohol use on percent heavy drinking days
(untransformed; n 99). Error bars represent the standard deviation. Used with permission from ref. 14.
Copyright © 2013 Wiley.
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placebo from the COMBINE study, which was a
multisite, randomized, double-blind, placebo-
controlled study of the combination of acampro-
sate and naltrexone and behavioral interventions
for alcohol dependence, Weiss and colleagues,48
demonstrated that participants assigned to pla-
cebo and a lower level of behavioral intervention,
medical management, had significantly higher
PDA than participants assigned to more intense
behavioral therapy without any pills. Retention
in the COMBINE study also was higher among
those receiving placebo plus medical manage-
ment than in the no-pill group.48 This points to
the potentially powerful effect of taking a pill and
suggests that patients with a goal of abstinence
who receive medication in a primary care setting
may be able to achieve substantial improvements
in alcohol use outcomes.
Study Limitations
Limitations to this study include exploratory anal-
yses, a small sample size, associations only, and
generalizability. Measurement issues also exist in
that drinking goal was only measured before study
enrollment and may have changed during the
course of treatment, which could affect outcomes.
In addition, readiness to change alcohol use was not
measured in the parent study and therefore could
not be used in our analyses. Specifically, for exam-
ple, taking action to change has been found to
predict less drinking among hospitalized medical
patients with risky alcohol use,49 a group in which
a large proportion have an alcohol use disorder.50
The generalizability of findings may also be limited
because most participants in the parent study were
recruited via advertisement to keep a steady flow of
participants enrolled, and those with a history of
alcohol withdrawal seizures or delirium tremens
were excluded; therefore, findings may not be typ-
ical of patients with an alcohol use disorder who are
seen in primary care. In addition, although there
was no effect of acamprosate found in the parent
study, the effect of the brief behavioral counseling
alone in this study could not be determined because
all participants were taking either acamprosate or
matching placebo pills. Finally, there was no treat-
ment follow-up in the parent study; therefore, the
durability of findings in our study could not be
examined.
Conclusion
Patients with an alcohol use disorder who have a
drinking goal of abstinence, especially consistent
daily drinkers, and who receive medication and
brief behavioral counseling may maximally benefit
from alcohol use disorder treatment in a primary
care setting.
The authors thank Dr. Richard Saitz for his insightful review
and critique of this article.
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